Gene therapy approaches for prevention of retinal degeneration in Usher syndrome.
作者信息
Williams D S, Chadha A, Hazim R, Gibbs D
机构信息
Stein Eye Institute, UCLA School of Medicine, Los Angeles, CA, USA.
Departments of Ophthalmology and Neurobiology, UCLA School of Medicine, Los Angeles, CA, USA.
出版信息
Gene Ther. 2017 Feb;24(2):68-71. doi: 10.1038/gt.2016.81. Epub 2017 Jan 5.
Abstract
摘要
相似文献
1
Gene therapy approaches for prevention of retinal degeneration in Usher syndrome.用于预防乌谢尔综合征视网膜变性的基因治疗方法。
Gene Ther. 2017 Feb;24(2):68-71. doi: 10.1038/gt.2016.81. Epub 2017 Jan 5.
2
Therapy strategies for Usher syndrome Type 1C in the retina.1C 型 Usher 综合征的视网膜治疗策略。
Adv Exp Med Biol. 2014;801:741-7. doi: 10.1007/978-1-4614-3209-8_93.
3
Gene Therapy for the Retinal Degeneration of Usher Syndrome Caused by Mutations in MYO7A.针对由MYO7A基因突变引起的Usher综合征视网膜变性的基因治疗
Cold Spring Harb Perspect Med. 2015 Jan 20;5(6):a017319. doi: 10.1101/cshperspect.a017319.
4
Retinal gene therapy with a large MYO7A cDNA using adeno-associated virus.使用腺相关病毒的大型 MYO7A cDNA 进行视网膜基因治疗。
Gene Ther. 2013 Aug;20(8):824-33. doi: 10.1038/gt.2013.3. Epub 2013 Jan 24.
5
AAV-Mediated Clarin-1 Expression in the Mouse Retina: Implications for USH3A Gene Therapy.腺相关病毒介导的Clarin-1在小鼠视网膜中的表达：对USH3A基因治疗的意义。
PLoS One. 2016 Feb 16;11(2):e0148874. doi: 10.1371/journal.pone.0148874. eCollection 2016.
6
Assessment of different virus-mediated approaches for retinal gene therapy of Usher 1B.评估不同病毒介导的方法在 Usher1B 视网膜基因治疗中的应用。
Adv Exp Med Biol. 2014;801:725-31. doi: 10.1007/978-1-4614-3209-8_91.
7
Gene therapy strategies for Usher syndrome type 1B.
Adv Exp Med Biol. 2012;723:235-42. doi: 10.1007/978-1-4614-0631-0_31.
8
[Molecular genetic study of Usher syndrome in Spain].[西班牙尤塞氏综合征的分子遗传学研究]
Acta Otorrinolaringol Esp. 2005 Aug-Sep;56(7):285-9. doi: 10.1016/s0001-6519(05)78616-7.
9
[Gene therapy progress: hopes for Usher syndrome].[基因治疗进展：对乌谢综合征的希望]
Med Sci (Paris). 2018 Oct;34(10):842-848. doi: 10.1051/medsci/2018210. Epub 2018 Nov 19.
10
Retinal Gene Therapy for Usher Syndrome: Current Developments, Challenges, and Perspectives.用于乌-韦综合征的视网膜基因治疗：当前进展、挑战与展望
Int Ophthalmol Clin. 2021 Oct 1;61(4):109-124. doi: 10.1097/IIO.0000000000000378.
引用本文的文献
1
Expression of two major isoforms of MYO7A in the retina: Considerations for gene therapy of Usher syndrome type 1B.两种主要 MYO7A 同工型在视网膜中的表达：对 1B 型 Usher 综合征基因治疗的思考。
Vision Res. 2023 Nov;212:108311. doi: 10.1016/j.visres.2023.108311. Epub 2023 Aug 15.
2
Therapeutic applications of CRISPR/Cas9 gene editing technology for the treatment of ocular diseases.CRISPR/Cas9 基因编辑技术在眼部疾病治疗中的治疗应用。
FEBS J. 2023 Nov;290(22):5248-5269. doi: 10.1111/febs.16771. Epub 2023 Mar 27.
3
The genetic and phenotypic landscapes of Usher syndrome: from disease mechanisms to a new classification.遗传性耳聋-视网膜色素变性综合征的遗传和表型图谱：从疾病机制到新分类
Hum Genet. 2022 Apr;141(3-4):709-735. doi: 10.1007/s00439-022-02448-7. Epub 2022 Mar 30.
4
Usher Syndrome: Genetics and Molecular Links of Hearing Loss and Directions for Therapy.尤塞氏综合征：听力损失的遗传学与分子联系及治疗方向
Front Genet. 2020 Oct 22;11:565216. doi: 10.3389/fgene.2020.565216. eCollection 2020.
5
Restoring Vision to the Blind with Chemical Photoswitches.用化学光开关使盲人重见光明。
Chem Rev. 2018 Nov 14;118(21):10748-10773. doi: 10.1021/acs.chemrev.7b00723. Epub 2018 Jun 6.
6
USH2A Gene Editing Using the CRISPR System.使用CRISPR系统对USH2A基因进行编辑
Mol Ther Nucleic Acids. 2017 Sep 15;8:529-541. doi: 10.1016/j.omtn.2017.08.003. Epub 2017 Aug 12.
本文引用的文献
1
In vivo genome editing via CRISPR/Cas9 mediated homology-independent targeted integration.通过CRISPR/Cas9介导的同源性非依赖靶向整合进行体内基因组编辑。
Nature. 2016 Dec 1;540(7631):144-149. doi: 10.1038/nature20565. Epub 2016 Nov 16.
2
Safety and durability of effect of contralateral-eye administration of AAV2 gene therapy in patients with childhood-onset blindness caused by RPE65 mutations: a follow-on phase 1 trial.RPE65基因突变所致儿童期失明患者对侧眼给予AAV2基因治疗的安全性及疗效持久性：一项1期随访试验
Lancet. 2016 Aug 13;388(10045):661-72. doi: 10.1016/S0140-6736(16)30371-3. Epub 2016 Jun 30.
3
CRISPR Repair Reveals Causative Mutation in a Preclinical Model of Retinitis Pigmentosa.CRISPR修复揭示色素性视网膜炎临床前模型中的致病突变。
Mol Ther. 2016 Aug;24(8):1388-94. doi: 10.1038/mt.2016.107. Epub 2016 May 20.
4
In vitro and in vivo rescue of aberrant splicing in CEP290-associated LCA by antisense oligonucleotide delivery.通过反义寡核苷酸递送对CEP290相关的莱伯先天性黑蒙症中异常剪接进行体外和体内挽救。
Hum Mol Genet. 2016 Jun 15;25(12):2552-2563. doi: 10.1093/hmg/ddw118. Epub 2016 Apr 22.
5
In Vivo CRISPR/Cas9 Gene Editing Corrects Retinal Dystrophy in the S334ter-3 Rat Model of Autosomal Dominant Retinitis Pigmentosa.体内CRISPR/Cas9基因编辑纠正常染色体显性视网膜色素变性S334ter-3大鼠模型中的视网膜营养不良。
Mol Ther. 2016 Mar;24(3):556-63. doi: 10.1038/mt.2015.220. Epub 2015 Dec 15.
6
Cpf1 is a single RNA-guided endonuclease of a class 2 CRISPR-Cas system.Cpf1是2类CRISPR-Cas系统中的一种单RNA引导的内切核酸酶。
Cell. 2015 Oct 22;163(3):759-71. doi: 10.1016/j.cell.2015.09.038. Epub 2015 Sep 25.
7
Improved dual AAV vectors with reduced expression of truncated proteins are safe and effective in the retina of a mouse model of Stargardt disease.表达截短蛋白减少的改良双腺相关病毒载体在斯塔加特病小鼠模型的视网膜中安全有效。
Hum Mol Genet. 2015 Dec 1;24(23):6811-25. doi: 10.1093/hmg/ddv386. Epub 2015 Sep 29.
8
CRISPR-Cas-mediated targeted genome editing in human cells.CRISPR-Cas介导的人类细胞靶向基因组编辑。
Methods Mol Biol. 2014;1114:245-67. doi: 10.1007/978-1-62703-761-7_16.
9
Genome engineering using the CRISPR-Cas9 system.使用 CRISPR-Cas9 系统进行基因组工程。
Nat Protoc. 2013 Nov;8(11):2281-2308. doi: 10.1038/nprot.2013.143. Epub 2013 Oct 24.
10
Effective delivery of large genes to the retina by dual AAV vectors.双腺相关病毒载体有效递送达视网膜的大基因。
EMBO Mol Med. 2014 Feb;6(2):194-211. doi: 10.1002/emmm.201302948. Epub 2013 Dec 15.
Zotero 插件